Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?
Journal of B.U.ON., cilt.24, sa.4, ss.1367-1370, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 24 Sayı: 4
- Basım Tarihi: 2019
- Dergi Adı: Journal of B.U.ON.
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1367-1370
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
Chemoradiotherapy (CRT) and chemotherapy in the perioperative or postoperative settings are the different neoadjuvant/adjuvant treatment approaches for resectable gastric cancer. After the results of the ARTIST trial, CRT lost its importance on a large scale in the adjuvant setting. Also, according to the results of the CRITICS trial, CRT does not seem beneficial in the perioperative treatment setting. The beneficial effect of neoadjuvant/adjuvant radiotherapy as a therapeutic option became more questionable as the evidence grows, but still needs further studies to identify its effects on a subgroup of patients who have R1 or